Open Access

REVIEW

Exploring exosomes to provide evidence for the treatment and prediction of Alzheimer’s disease

XIANGYU QUAN¹, XUETING MA¹, GUODONG LI², XUEQI FU¹, JIANGTAO LI¹, LINLIN ZENG^1,*

1 Edmond H. Fischer Signal Transduction Laboratory, School of Life Sciences, Jilin University, Changchun, 130012, China
2 Department of General Surgery, The Second Hospital of Jilin University, Changchun, 130041, China

* Corresponding Author: LINLIN ZENG. Email:

(This article belongs to the Special Issue: Novel Biomarkers in Diseases for Detection, Diagnosis, and Prognosis)

BIOCELL 2023, 47(10), 2163-2176. https://doi.org/10.32604/biocell.2023.031226

Received 23 May 2023; Accepted 22 June 2023; Issue published 08 November 2023

Abstract

Exosomes are extracellular vesicles with a 30–150 nm diameter originating from endosomes. In recent years, scientists have regarded exosomes as an ideal small molecule carrier for the targeted treatment of Alzheimer’s disease (AD) across the blood-brain barrier due to their nanoscale size and low immunogenicity. A large amount of evidence shows that exosomes are rich in biomarkers, and it has been found that the changes in biomarker content in blood, cerebrospinal fluid, and urine are often associated with the onset of AD patients. In this paper, some recent advances in the use of exosomes in the treatment of AD are reviewed, and various exosome markers and some latest detection methods are summarized to provide some evidence for the detection or treatment of AD by exosomes.

---

Graphical Abstract

---

Keywords

---